e-learning
resources
Vienna 2009
Monday, 14.09.2009
Tuberculosis control
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Revised CAT II regimen as an alternative strategy for re-treatment of CAT I regimen failure and irregular treatment cases
P. Tabarsi, V. Tabatabaei, E. Chitsaz, P. Baghaei, M. Marjani, M. Shamaei, M. Amiri, D. Mansouri, M. Masjedi, M. van der Werf (Tehran, Islamic Republic Of Iran; The Hague, Netherlands)
Source:
Annual Congress 2009 - Tuberculosis control
Session:
Tuberculosis control
Session type:
Thematic Poster Session
Number:
2609
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
P. Tabarsi, V. Tabatabaei, E. Chitsaz, P. Baghaei, M. Marjani, M. Shamaei, M. Amiri, D. Mansouri, M. Masjedi, M. van der Werf (Tehran, Islamic Republic Of Iran; The Hague, Netherlands). Revised CAT II regimen as an alternative strategy for re-treatment of CAT I regimen failure and irregular treatment cases. Eur Respir J 2009; 34: Suppl. 53, 2609
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Outcome in DOTS category II patients by strengthening the regimen with daily levofloxacin
Source: Annual Congress 2009 - Tuberculosis control
Year: 2009
Short 12-month regimen with intravenouse linezolid for MDR-TB: treatment outcomes and first follow up results.
Source: International Congress 2018 – New developments in tuberculosis
Year: 2018
Impact of drug resistance over sputum conversion in tubercular patients receiving re-treatment regimen
Source: Annual Congress 2011 - Epidemiology of multidrug-resistant and extensively drug-resistant tuberculosis
Year: 2011
Use of shortened chemotherapy regimens in treatment of adolescents with MDR/XDR TB
Source: International Congress 2018 – Drug-resistant tuberculosis and the sequelae of pulmonary tuberculosis
Year: 2018
The assessment of the efficacy of a standard chemotherapy regimen in the treatment of new sputum-positive tuberculosis (TB) patients
Source: Eur Respir J 2001; 18: Suppl. 33, 340s
Year: 2001
Safety and acceptability of a 4-drug fixed-dose combination regimen compared with separate drugs for treatment of pulmonary tuberculosis
Source: International Congress 2016 – Treatment management options and costs: vitamin D, Matrix metalloproteinases (MMPs), nutrition, and human genetics
Year: 2016
Pattern of drug resistance among patients who fail Cat II regimen and patients who fail standard treatment: is there any difference?
Source: Eur Respir J 2006; 28: Suppl. 50, 378s
Year: 2006
Resistance pattern to WHO CAT IV regimen in patients suspected of drug resistance tuberculosis presenting to a specialist office practice in Mumbai
Source: Annual Congress 2011 - Epidemiology of multidrug-resistant and extensively drug-resistant tuberculosis
Year: 2011
Impact of pre-treatment duration by first line drugs on treatment outcomes of patients with MDR-TB
Source: International Congress 2015 – TB treatment: new drugs and drug resistance
Year: 2015
Efficacy of linezolide-free chemotherapy schemes in patients with highly drug-resistant tuberculosis
Source: Virtual Congress 2021 – The ongoing threat of drug-resistant tuberculosis
Year: 2021
Cost-effectiveness analysis of regimens chemotherapy in patients with multidrug resistant tuberculosis (MDR TB) compared with standard regimen in patients with susceptible MBT
Source: Eur Respir J 2003; 22: Suppl. 45, 526s
Year: 2003
To study outcome of directly observered treatment shortcourse (DOTS) category I and category II relapses when put on re-treatment regimen (Cat-II DOTS)
Source: Annual Congress 2011 - Tuberculosis epidemiology and public health
Year: 2011
Impact of XDR-TB on treatment outcome of MDR-TB patients with standardized regimens
Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis
Year: 2008
Early experience with the implementation of the WHO shorter MDR-TB treatment regimen in Singapore
Source: International Congress 2018 – Drug-resistant tuberculosis
Year: 2018
Treatment outcomes of new cases of polyresistant pulmonary TB with second line anti-TB drugs in DOTS-Plus regimen
Source: Eur Respir J 2002; 20: Suppl. 38, 359s
Year: 2002
Weekly chemotherapy with cisplatin/paclitaxel in the front-line treatment of NSCLC: a phase II study
Source: Eur Respir J 2004; 24: Suppl. 48, 672s
Year: 2004
Glucocorticosteroid treatment in sarcoidosis: comparison of regimens
Source: Eur Respir J 2003; 22: Suppl. 45, 234s
Year: 2003
Outcomes of drug-resistant TB cases undergoing bedaquiline (BQ)-treatment and adjunctive surgery
Source: International Congress 2018 – Drug-resistant tuberculosis
Year: 2018
Three drug regimen in SCLC-ED patients: a phase II study
Source: Annual Congress 2007 - Therapy of thoracic malignancies
Year: 2007
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept